Definitive Contract 75A50121C00060
Award Date
6/11/21
Potential Completion Date
3/31/23
Potential Value
$749K
Awardee
Bioaegis Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Morristown, NJ 07960, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
10
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $20,000,000.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Bioaegis Therapeutics Inc. The contract is for the development of BIOAEGIS: Plasma Gelsolin (PGSN), an abundant, circulating protein that modulates inflammation and enhances host defenses against pathogens, for the treatment of Acute Respiratory Distress Syndrome. The contract has an ultimate completion date of August 31, 2027 and...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Esperovax Inc. a $484,643 firm fixed price definitive contract to develop host-directed therapeutic candidates for mitigating long-term effects of respiratory distress. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought proposals for candidates aiding long-term outcomes from lung injury through Area of...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $27,992,718.00 definitive contract to Inflammatix, Inc., a self-certified small disadvantaged business organization, for the development of "a full stack of host-response solutions to infectious disease testing to address outpatient and inpatient testing for acute infections and sepsis both during and outside of influenza season." This contract, which has a...
Sentien Biotechnologies, Inc. was awarded a $510,265 definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to conduct research and development of ex vivo cell therapy. The contract was awarded under Special Instructions 019 of the Easy Broad Agency Announcement BAA-20-100-SOL-0002, which sought host-directed therapeutic candidates to aid long-term outcomes from lung injury. Sentien Biotechnologies will pursue safety...
This federal contract award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Inflammatix, Inc., a small disadvantaged business. The $749,999 firm fixed-price contract supports research and development for the Triverity cartridge, a diagnostic tool focused on infection severity and sepsis detection, under Area of Interest #2 of ASPR's Easy Broad Agency Announcement. The...
This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Inflammatix, Inc., a self-certified small disadvantaged business. The contract is for the development of the HOSTDX-Sepsis diagnostic test, a rapid point-of-care test that analyzes the host immune response to detect and classify sepsis. The contract has a firm fixed price of $510,000.00 and a completion date of November 30, 2021....
Partner Therapeutics, Inc. was awarded a $748,912 definite contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to conduct research and development of diagnostic tests for patients with sepsis and immunoparalysis. The contract was awarded under Special Instructions 019 of the agency's Easy Broad Agency Announcement BAA-20-100-SOL-0002 vehicle. Special Instructions 019 sought host-directed therapeutic candidates to aid long-term...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This federal contract award, valued at $749,549.00, was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Immunexpress Inc., a for-profit foreign-owned company. The contract is for the "ASSESSMENT & TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS" and is a definitive, firm-fixed-price contract with a period of performance ending on June 10, 2023. The contract award originated from a Broad...
The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $70,000 firm fixed-price contract to Oncotelic Inc. to develop TGF-β therapeutics against the long-term effects of respiratory distress post COVID-19. The contract, which does not have a set-aside designation, has a period of performance ending on June 30, 2023. This contract supports the agency's efforts to address the medical challenges posed by the COVID-19 pandemic.